Thompson Siegel & Walmsley LLC Cuts Stake in Pfizer Inc. (NYSE:PFE)

Thompson Siegel & Walmsley LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 19.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 387,084 shares of the biopharmaceutical company’s stock after selling 92,801 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in Pfizer were worth $11,202,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of PFE. China Universal Asset Management Co. Ltd. purchased a new stake in Pfizer during the 1st quarter worth about $315,000. Edgestream Partners L.P. purchased a new stake in Pfizer during the first quarter valued at about $243,000. Stonebridge Capital Advisors LLC increased its stake in Pfizer by 35.2% during the first quarter. Stonebridge Capital Advisors LLC now owns 26,586 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 6,921 shares during the last quarter. Gamco Investors INC. ET AL lifted its stake in shares of Pfizer by 123.9% in the 1st quarter. Gamco Investors INC. ET AL now owns 533,251 shares of the biopharmaceutical company’s stock valued at $14,798,000 after purchasing an additional 295,139 shares in the last quarter. Finally, Gabelli Funds LLC grew its holdings in shares of Pfizer by 23.1% during the 1st quarter. Gabelli Funds LLC now owns 710,413 shares of the biopharmaceutical company’s stock worth $19,714,000 after purchasing an additional 133,200 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PFE. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $32.92.

Insider Activity

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

PFE opened at $25.06 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business’s 50-day simple moving average is $28.28 and its 200 day simple moving average is $28.58. The firm has a market capitalization of $142.03 billion, a PE ratio of 33.87, a PEG ratio of 0.80 and a beta of 0.67. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the company earned ($0.17) earnings per share. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.70%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.